Cargando…

The expression of the adenosine pathway markers CD39 and CD73 in salivary gland carcinomas harbors the potential for novel immune checkpoint inhibition

BACKGROUND: In salivary gland carcinomas (SGC), there is only a small fraction of entities that appears to profit from immune checkpoint inhibition (ICI). Recent findings connected the activation of adenosine-signaling with a tolerogenic microenvironment. Therefore, the inhibition of adenosine pathw...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bauer, Arthur, Gebauer, Niklas, Knief, Juliana, Tharun, Lars, Arnold, Nele, Riecke, Armin, Steinestel, Konrad, Witte, Hanno M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314850/ https://www.ncbi.nlm.nih.gov/pubmed/35902382 http://dx.doi.org/10.1007/s00432-022-04211-x

Ejemplares similares

Prognostic Impact of PD-L1 Expression in Malignant Salivary Gland Tumors as Assessed by Established Scoring Criteria: Tumor Proportion Score (TPS), Combined Positivity Score (CPS), and Immune Cell (IC) Infiltrate
por: Witte, Hanno M., et al.
Publicado: (2020)

The Role of Ectonucleotidases CD39 and CD73 and Adenosine Signaling in Solid Organ Transplantation
por: Roberts, Veena, et al.
Publicado: (2014)

Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression
por: Deaglio, Silvia, et al.
Publicado: (2007)

The adenosine generating enzymes CD39/CD73 control microglial processes ramification in the mouse brain
por: Matyash, Marina, et al.
Publicado: (2017)

The Glasgow Prognostic Score Predicts Survival Outcomes in Neuroendocrine Neoplasms of the Gastro–Entero–Pancreatic (GEP-NEN) System
por: Gebauer, Niklas, et al.
Publicado: (2022)

Relationship between the Gene Expression of Adenosine Kinase Isoforms and the Expression of CD39 and CD73 Ectonucleotidases in Colorectal Cancer
por: Zhulai, G. A., et al.
Publicado: (2023)

Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade
por: Yang, Rui, et al.
Publicado: (2020)

Bispecific antibody CD73xEGFR more selectively inhibits the CD73/adenosine immune checkpoint on cancer cells and concurrently counteracts pro-oncogenic activities of CD73 and EGFR
por: Ploeg, Emily Maria, et al.
Publicado: (2023)

Changes in CD73, CD39 and CD26 expression on T-lymphocytes of ANCA-associated vasculitis patients suggest impairment in adenosine generation and turn-over
por: Kling, Lovis, et al.
Publicado: (2017)

Skewed CD39/CD73/adenosine pathway contributes to B-cell hyperactivation and disease progression in patients with chronic hepatitis B
por: Zhou, Shuang-Nan, et al.
Publicado: (2020)

Phenotypical analysis of ectoenzymes CD39/CD73 and adenosine receptor 2A in CD4(+) CD25(high)Foxp3(+) regulatory T‐cells in psoriasis
por: Han, Ling, et al.
Publicado: (2017)

CD39/CD73 Dysregulation of Adenosine Metabolism Increases Decidual Natural Killer Cell Cytotoxicity: Implications in Unexplained Recurrent Spontaneous Abortion
por: Zhu, Jianan, et al.
Publicado: (2022)

Low expression of CD39 and CD73 genes in centenarians compared with octogenarians
por: Crooke, Almudena, et al.
Publicado: (2017)

Monitoring and characterizing soluble and membrane-bound ectonucleotidases CD73 and CD39
por: Goueli, Said A., et al.
Publicado: (2019)

CD39 and CD73 as Promising Therapeutic Targets: What Could Be the Limitations?
por: Battastini, Ana Maria Oliveira, et al.
Publicado: (2021)

CD39/CD73/A2AR pathway and cancer immunotherapy
por: Xia, Chenglai, et al.
Publicado: (2023)

The ectonucleotidases CD39 and CD73 on T cells: The new pillar of hematological malignancy
por: Jiang, Xuan, et al.
Publicado: (2023)

Exploring CD39 and CD73 Expression as Potential Biomarkers in Prostate Cancer
por: Gardani, Carla Fernanda Furtado, et al.
Publicado: (2023)

The Glasgow Prognostic Score at Diagnosis Is a Predictor of Clinical Outcome in Patients with Multiple Myeloma Undergoing Autologous Haematopoietic Stem Cell Transplantation
por: Witte, Hanno M., et al.
Publicado: (2020)

Nucleotide Analog ARL67156 as a Lead Structure for the Development of CD39 and Dual CD39/CD73 Ectonucleotidase Inhibitors
por: Schäkel, Laura, et al.
Publicado: (2020)

High Expression of Ecto-Nucleotidases CD39 and CD73 in Human Endometrial Tumors
por: Aliagas, Elisabet, et al.
Publicado: (2014)

CD39/Adenosine Pathway Is Involved in AIDS Progression
por: Nikolova, Maria, et al.
Publicado: (2011)

Defining the CD39/CD73 Axis in SARS-CoV-2 Infection: The CD73(-) Phenotype Identifies Polyfunctional Cytotoxic Lymphocytes
por: Ahmadi, Parimah, et al.
Publicado: (2020)

Prognostic impact of nutritional and inflammation-based risk scores in follicular lymphoma in the era of anti-CD20 targeted treatment strategies
por: Gebauer, Niklas, et al.
Publicado: (2021)

Human Gingiva-Derived Mesenchymal Stem Cells Inhibit Xeno-Graft-versus-Host Disease via CD39–CD73–Adenosine and IDO Signals
por: Huang, Feng, et al.
Publicado: (2017)

Enhanced expression of CD39 and CD73 on T cells in the regulation of anti-tumor immune responses
por: Shevchenko, Ivan, et al.
Publicado: (2020)

A Novel Bispecific Antibody for EpCAM-Directed Inhibition of the CD73/Adenosine Immune Checkpoint in Ovarian Cancer
por: Ploeg, Emily Maria, et al.
Publicado: (2023)

Roles of the Adenosine Receptor and CD73 in the Regulatory Effect of γδ T Cells
por: Liang, Dongchun, et al.
Publicado: (2014)

The Inhibition of CD39 and CD73 Cell Surface Ectonucleotidases by Small Molecular Inhibitors Enhances the Mobilization of Bone Marrow Residing Stem Cells by Decreasing the Extracellular Level of Adenosine
por: Adamiak, Mateusz, et al.
Publicado: (2019)

Adenosine-generating ovarian cancer cells attract myeloid cells which differentiate into adenosine-generating tumor associated macrophages – a self-amplifying, CD39- and CD73-dependent mechanism for tumor immune escape
por: Montalbán del Barrio, Itsaso, et al.
Publicado: (2016)

On the mechanism of anti-CD39 immune checkpoint therapy
por: Allard, David, et al.
Publicado: (2020)

Resident Cardiac Immune Cells and Expression of the Ectonucleotidase Enzymes CD39 and CD73 after Ischemic Injury
por: Bönner, Florian, et al.
Publicado: (2012)

Helios, CD73 and CD39 Induction in Regulatory T Cells Exposed to Adipose Derived Mesenchymal Stem Cells
por: Fakhimi, Maryam, et al.
Publicado: (2020)

Targeting the Immunomodulatory CD73/Adenosine System to Improve the Therapeutic Gain of Radiotherapy
por: de Leve, Simone, et al.
Publicado: (2019)

A Novel Antagonistic CD73 Antibody for Inhibition of the Immunosuppressive Adenosine Pathway
por: Wurm, Melanie, et al.
Publicado: (2021)

Tumor intrinsic and extrinsic functions of CD73 and the adenosine pathway in lung cancer
por: Kowash, Ryan R., et al.
Publicado: (2023)

Cytokine-Induced Killer Cells Express CD39, CD38, CD203a, CD73 Ectoenzymes and P1 Adenosinergic Receptors
por: Horenstein, Alberto L., et al.
Publicado: (2018)

The Clinical Significance of CD73 in Cancer
por: Bach, Niklas, et al.
Publicado: (2023)

Feed-Forward Inhibition of CD73 and Upregulation of Adenosine Deaminase Contribute to the Loss of Adenosine Neuromodulation in Postinflammatory Ileitis
por: Vieira, Cátia, et al.
Publicado: (2014)

CD73 Rather Than CD39 Is Mainly Involved in Controlling Purinergic Signaling in Calcified Aortic Valve Disease
por: Kudryavtsev, Igor, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_baleku6mf8hjjgl2knqolae5d7